[Topiramate in comorbid disorders: epilepsy and migraine].
BACKGROUND
With relative frequency epilepsy and migraine are associated in a same patient. Some times it is difficult to distinguish an attack of others. Reason why it would be of utility to have a treatment effective in both pathologies. It is tried to study in patients with this comorbidity, how of effective it is a drug indicated in the two pathologies, as it is topiramate.


METHODS
An observational, longitudinal and prospective study is made, where 15 patients are recruited with this association, and which they were treated with topiramate. They are revaluated at three and six months of treatment.


RESULTS
Significant differences are obtained (p < 0.05) in all the studied variables (severity and duration of the migraine attacks and frequency of the migraine and epileptic attacks), with a medium dose of 100 mg/day of topiramate, at the end of the study. Not serious adverse effects were observed.


CONCLUSIONS
Topiramate in monotherapy seems to be a suitable treatment in patients who undergo epileptic and migrainous attacks jointly.
Dorado
R
R
Departamento de Neurología, Sanatorio Nuestra Señora del Rosario, Madrid.
Gómez-Arguelles
J M
JM
Herrera
A
A
Aragón
E
E
Blanco
M
M
Gilo-Arrojo
F
F
Sepúlveda-Sánchez
J M
JM
González de la Aleja
J
J
Anciones
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use*; D015897:Comorbidity; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011446:Prospective Studies; D000077236:Topiramate
D000927:Anticonvulsants; D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose